Arbutus Biopharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 8 Sell calls were followed by a 5% average decline over the next quarter.
- Recent price momentum is -10.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 10.0% of float.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation B-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 3.6x | Better than 98% |
| Price / Sales | 3.5x | Better than 36% |
| P/E vs own 5-yr range | 90th pctl | Better than 15% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | -19.5% | Better than 1% |
| Operating margin | -192.1% | Better than 5% |
| Net margin | -237.9% | Better than 5% |
| Return on equity | -38.5% | Better than 11% |
| Return on invested capital | -42.6% | Better than 7% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -22.8% | Better than 26% |
| 6-month return | -7.6% | Better than 43% |
| 12-month return (ex latest month) | -2.6% | Better than 31% |
| Distance below 52-week high | 26.2% | Better than 48% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 15.7x | Better than 97% |
| Debt to assets | 0.8% | Better than 94% |
| Interest coverage | -344.4x | Better than 3% |
| Free cash flow / net income | 111.0% | Better than 46% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 4.07
- Open
- 4.01
- Day range
- 3.97 - 4.09
- Avg price
- 4.04
- Volume
- 2.99M
- Turnover
- 12.08M
- Turnover ratei
- 2.63%
- Volume ratioi
- 1.05
- Amplitudei
- 2.95%
- 52-week rangei
- 3.50 - 5.45
Valuation
- P/Ei
- -23.65
- P/E (TTM)i
- 3.59
- P/Bi
- 7.19
- EPSi
- -0.17
- Book value / shi
- 0.56
- Net profit
- -26.06M
- Net assets
- 85.69M
Share structure
- Market cap
- 616.24M
- Float capi
- 457.21M
- Shares out
- 153.29M
- Float sharesi
- 113.73M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-05-04
26.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+59.09K net over the window
Short interest
- Shares short
- 19.89M
- % of floati
- 10.04%
- Days to coveri
- 9.14
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Arbutus Biopharma (ABUS)?
Arbutus Biopharma last traded at 4.02. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Arbutus Biopharma's market cap?
About 616.24M.
What is the P/E ratio of Arbutus Biopharma?
The trailing twelve-month P/E is 3.59. The Valuation tab shows it against the stock's own five-year range.
Does Arbutus Biopharma pay a dividend?
Arbutus Biopharma does not currently pay a regular dividend.
What is Arbutus Biopharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Arbutus Biopharma a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:39:17 · For reference only, not investment advice and not tailored to your situation.
Arbutus Biopharma discussion 0 comments